Evaluating Verastem (NASDAQ: VSTM) as a multi-year investment requires assessing clinical trial success rates, regulatory approval pathways for its oncology pipeline, and market adoption rates for its commercial therapies, which carry high growth potential alongside substantial clinical risk.